1. Will other drugmakers end up with deals like Endo’s $10M opioid settlement? — AstraZeneca Imfinzi combo fails advanced lung cancer study — FDA says they were “lucky” with Novartis data manipulation controversy — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Insider Trading

Discussion in 'Amgen IT' started by Anonymous, Oct 3, 2008 at 6:21 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

  2. Anonymous

    Anonymous Guest

    and gone.
     
  3. Anonymous

    Anonymous Guest

    It's about time that something caught up to that unethical little shit.
     
  4. Anonymous

    Anonymous Guest

    Ex-CEO, friend settle insider-trading case
    Henry K. Lee, Chronicle Staff Writer

    Thursday, October 2, 2008

    (10-01) 06:48 PDT SAN JOSE --

    The former president and CEO of a Santa Clara technology company and his childhood friend have been charged with insider trading for allegedly netting more than $85,000 in illegal profits.

    Elias Antoun, 52, of San Jose, the former head of Genesis Microchip Inc., and his friend, Samir Abed, 54, of Thousand Oaks (Ventura County) were named in a complaint filed by the U.S. Securities and Exchange Commission. Both have agreed to settle the case without admitting wrongdoing, the SEC said.

    Antoun bought 12,250 shares of Genesis stock in the brokerage accounts of a relative and a friend in fall 2007 while the company was in the middle of confidential merger negotiations with STMicroelectronics of Geneva, one of the world's largest semiconductor companies, according to the complaint filed Tuesday in U.S. District Court in San Jose.

    Abed, who became friends with Antoun after the two attended boarding school together in the 1960s, bought 11,000 shares of Genesis stock and 100 call-option contracts after learning of the merger negotiations from Antoun, the SEC said.

    Antoun netted profits of $33,975 and Abed netted $51,206 when the merger was announced in December and Genesis' stock price skyrocketed 57 percent, the SEC said.

    Antoun has agreed to pay $37,299 and a financial penalty of $36,210 to settle the case. Abed has agreed to pay $53,362.62 and a penalty of $25,603. Both Antoun and Abed have also agreed to be enjoined from future violations of the securities laws. Abed cooperated with the investigation, the SEC said.

    Antoun has previously been involved in insider trading, the SEC said. In July 2006, Antoun bought 900 shares of Genesis stock in a friend's account in advance of a Genesis earnings announcement, the complaint said. He netted a profit of $2,235, authorities said.


    E-mail Henry K. Lee at hlee@sfchronicle.com.

    http://sfgate.com/cgi-bin/article.cgi?f=/c/a/2008/10/02/BUI2139GRF.DTL

    This article appeared on page C - 3 of the San Francisco Chronicle
     
  5. Anonymous

    Anonymous Guest

    He did it because his own company stock didn't do jack diddly, what's the point of being in mgt if the shares are worthless.

    Enjoy bread and water for dinner, breakfast and midday meals.